GSK ended development of camlipixant after mixed results in two Phase 3 trials in refractory chronic cough. In Calm-1, the 50 mg twice-daily dose met its primary endpoint at week 12, but Calm-2 failed at week 24, and the 25 mg dose did not succeed in either study. GSK said the “limited efficacy” is unlikely to transform patient care and shut the indication, a blow to respiratory blockbuster hopes attached to its 2023 Bellus Health buyout. Trevi Therapeutics’ competing nalbuphine ER program (Haduvio) stands to benefit as investors reassess the crowded chronic cough landscape.